Endocrinology and Metabolism (Seoul, Korea), 32 (2), 248256
The approval of oral semaglutide expanded the range of medically supported weight loss therapies by introducing a non-injectable GLP-1 option
GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach
2 Have your prescriber submit the prior-authorization through CarelonRx The PA submission requires: a documented T2D diagnosis (ICD-10 E11.x), evidence of metformin use or a documented reason you cannot take it, and on some Anthem plans documentation of an additional oral antidiabetic agent trial
Ensuring that their diet still contains an adequate amount of protein, vitamins, and minerals, including iron and zinc
For example, both medications have a relatively favorable side effect profile compared to other drugs in their respective classes, but the combination should be monitored closely for any unexpected reactions or adverse effects